We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Diabetes Researchers Convert Stem Cells into Insulin-Producing Cells

By LabMedica International staff writers
Posted on 11 Dec 2018
A team of stem cell biologists working on the problem of pancreas replacement in patients with type I diabetes identified the extrinsic and intrinsic signaling mechanisms that coordinate the fate-determining transcriptional events underlying the maturation of bipotent pancreatic progenitors and used this information to convert these pancreatic progenitors - derived from human embryonic stem cells - to insulin-producing islet cells.

The pancreas originates from two epithelial evaginations (meaning to turn an organ or part inside out) of the foregut, which consist of multipotent epithelial progenitor cells that organize into a complex tubular epithelial network. More...
The trunk domain of each epithelial branch consists of bipotent pancreatic progenitors that give rise to both duct and endocrine lineages.

Investigators at Helmholtz Zentrum München (Munich, Germany) reported in the November 28, 2018, online edition of the journal Nature that single-cell analysis of pancreatic bipotent pancreatic progenitors derived from human embryonic stem cells revealed that cell confinement was a prerequisite for endocrine specification, whereas spreading drove the progenitors towards a ductal fate. Mechanistic studies identified the interaction of extracellular matrix (ECM) with integrin alpha5 as the extracellular cue that controlled the fate of bipotent pancreatic progenitors.

While ECM-integrin alpha5 signaling promoted differentiation towards the duct lineage, disruption of this signaling cascade stimulated hormone development. This cascade could be disrupted genetically or with drugs to convert bipotent pancreatic progenitors derived from human embryonic stem cells into hormone-producing islet cells.

"We have now been able to map the signal that determines whether pancreatic progenitor cells will become endocrine, such as insulin-producing beta cells or duct cells", said senior author Dr. Henrik Semb, director of the institute of translational stem cell research at Helmholtz Zentrum München. "The cells are analogous to pinballs, whose ultimate score is based on the sum of pin encounters. They are constantly moving around within the developing pancreas, leading to frequent environmental changes. We show that the exposure to specific extracellular matrix components determines the ultimate destiny of the cells."

"We can now replace significant numbers of empirically derived substances, whose mode of action in current state-of-the-art differentiation protocols is largely unknown, with small molecule inhibitors that target specific components of the newly identified mechano-signaling pathway," said Dr. Semb. "Our discovery breaks new ground because it explains how multipotent progenitor cells mature into different cell types during organ formation. It also gives us the tools to recreate the processes in the laboratory, to more precisely engineer cells that are lost or damaged in severe diseases, such as type I diabetes and neurodegenerative diseases, for future cell replacement therapies."

Related Links:
Helmholtz Zentrum München


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Automatic Hematology Analyzer
LABAS F9000
New
Automated PCR System
OnePCR
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.